In short
Sino Biopharmaceutical Limited (1177.HK) has net income down 33.0% to CNY 2.3B and EPS (Diluted) down 32.1% to CNY 0.13 year on year. Its net margin is 7.4% and gross margin 82.1%, and it trades at 36.1× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
HK$5.41
HK$96.4B
9.6x
2.59%
52-Week Range
4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)
PEG 0.68 — below growth rate.
FCF yield 7.9% — strong cash generation.
Based on filing period ending Dec 2025
International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.
🇭🇰 Hong Kong Macro Indicators
Full dashboard →CPI Inflation
1.44%→
Near target
GDP Growth
3.49%↑
Strong
USD/HKD
7.85→
Current Account
12.25% GDP↑
Surplus
CPI inflation is 1.4% year-over-year (inflation near target); GDP growth is 3.5% year-over-year (moderate growth); USD/HKD is at 7.8470.
SWOT Analysis — 1177.HK
Inflationary BoomStrengths
Operating Cash Flow: CNY 9.3B (+40.5% YoY) — Operating cash flow grew 40% — the business generated more cash from day-to-day operations.
Total Assets: CNY 76.0B (+16.2% YoY) — Total assets grew 16% — the company's resource base expanded.
Gross Profit: CNY 26.1B (+11.0% YoY) — Gross profit rose 11% — the spread between revenue and direct costs improved.
Weaknesses
Net Income: CNY 2.3B (-33.0% YoY) — Profit fell 33% but remained positive.
EPS (Diluted): CNY 0.13 (-32.1% YoY) — Earnings per share fell 32%.
Opportunities
No clear opportunities identified at this time.
Threats
No significant threats flagged.
Financial Charts
Year-over-Year Changes
Operating Cash Flow
CNY 9.3B
was CNY 6.6B
Operating cash flow grew 40% — the business generated more cash from day-to-day operations.
Net Income
CNY 2.3B
was CNY 3.5B
Profit fell 33% but remained positive.
EPS (Diluted)
CNY 0.13
was CNY 0.19
Earnings per share fell 32%.
Total Assets
CNY 76.0B
was CNY 65.4B
Total assets grew 16% — the company's resource base expanded.
Gross Profit
CNY 26.1B
was CNY 23.5B
Gross profit rose 11% — the spread between revenue and direct costs improved.
Price HistoryHKD
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Research Sino Biopharmaceutical Limited
Data sourced from HKEX, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.